The weight-loss drug can cost patients more than $1,000 a month if they do not have health insurance coverage.
Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
Verywell Health on MSN3d
Novo Nordisk Offers Wegovy for $499 a Month in Direct-to-Consumer ProgramNovo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.
Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.
3don MSN
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Zacks Investment Research on MSN3d
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
Zeroing in on Eli Lilly, the company is already well established with Zepbound, which should continue to sell briskly as the world waits for a more powerful and efficacious obesity drug to hit the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback